Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128 plus endocrine therapy in ER-positive/HER2-negative advanced breast cancer after progression on everolimus
2014-001921-34Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sapanisertib in breast cancer (2 arms), sponsored by Millennium Pharmaceuticals. Started Nov 2014; status: completed.
02
Drugs
sapanisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-001921-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001921-34.